Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13891602 | 0.88 | GCK (0.62) | GCKRARG | |
| SCHEMBL1146572 | 0.88 | GCK (0.62) | GCKRARG | |
| SCHEMBL1146573 | 0.87 | GCK (0.43) | GCKRARGHSD17B10LMNAP2RX3 | |
| SCHEMBL12858604 | 0.86 | GCK (0.53) | GCKRARGDHODH | |
| SCHEMBL1796232 | 0.83 | HSD17B10 (0.47) | GCKHSD17B10LMNASMN1; SMN2KDM4E | |
| SCHEMBL1107452 | 0.79 | GCK (0.54) | GCK | |
| SCHEMBL9072499 | 0.79 | CA12 (0.56) | HSD17B10LMNASMN1; SMN2KDM4ECA12 | |
| SCHEMBL12774009 | 0.79 | CA12 (0.56) | HSD17B10LMNASMN1; SMN2KDM4ECA12 | |
| SCHEMBL1262502 | 0.79 | GCK (0.53) | GCKRARG | |
| SCHEMBL1262405 | 0.76 | S1PR2 (0.47) | GCKRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | GCK, GCKR, GRK4 | GCK 1/4885RARG 1849/4885HSD17B10 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.